Meribeth A Ogrinc is a Syracuse, New York based female rheumatologist who is specialized in Rheumatology. Active license number of Meribeth A Ogrinc for Rheumatology is 220800 in New York. Meribeth A Ogrinc treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Meribeth A Ogrinc speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
MD
Gender:
Female
Practice Address:
90 Presidential Plz, Rheumatology, Firm C, Syracuse, New York, 13202-2240
Phone:
315-464-3836
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1033147079
NPI Enumeration Date:
29 Jun, 2006
NPI Last Update On:
06 Oct, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Meribeth A Ogrinc are as mentioned below.
License Number
Specialization
State
Status
220800
Rheumatologist
New York
Primary
220800
Internal Medicine
New York
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
750 E Adams St, Syracuse, New York
Zip:
13210-2306
Phone Number:
--
Fax Number:
--
Patients can reach Meribeth A Ogrinc at 90 Presidential Plz, Rheumatology, Firm C, Syracuse, New York or can call to book an appointment on 315-464-3836. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.